Lv4
486 积分 2023-05-29 加入
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1个月前
已完结
Vebreltinib effective in MET-amplified NSCLC
1个月前
已完结
Targeting MET-mediated TKI resistance in EGFR-mutant NSCLC
1个月前
已完结
Standardising MET amplification testing: limitations of the GCN ≥6 criterion
1个月前
已完结
[Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer]
1个月前
已完结
[Expert consensus on diagnosis and treatment of advanced non-small cell lung cancer with HER-2 alterations (2025 edition)]
2个月前
已完结
[Clinical practice guideline for molecular pathology in colorectal cancer (2025 version)]
2个月前
已完结
[Guidelines for HER2 detection in gastric cancer(2016)]
2个月前
已完结
[Guideline for HER2 testing in breast cancer (2024 version)]
3个月前
已完结
[Guidelines on clinical practice of molecular tests in breast cancer in China (2025 edition)]
3个月前
已完结
皖公网安备34019202002308
